• Publications
  • Influence
ABO Incompatible Kidney Transplantations Without Splenectomy, Using Antigen‐Specific Immunoadsorption and Rituximab
ABO incompatible kidney transplantations have previously only been performed after several preoperative sessions of plasmapheresis and splenectomy, with the conventional triple‐drug immunosuppressiveExpand
  • 295
  • 14
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial
Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial assessed the feasibilityExpand
  • 231
  • 13
Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells.
The immunological rejection of HLA-identical kidney transplants indicates that non-HLA antigens may also be targets for transplant rejection. Interest in the possible role of endothelial specificExpand
  • 121
  • 8
ABO-Incompatible Kidney Transplantation Using Antigen-Specific Immunoadsorption and Rituximab: A 3-Year Follow-up
Background. In 2001 a protocol for ABO-incompatible (ABOi) kidney transplantation based on antigen-specific immunoadsorption and rituximab was introduced at our center, short-term results beingExpand
  • 149
  • 7
Kidney donors live longer.
BACKGROUND A very important issue in living kidney donor transplantation is whether the donation is safe for the donor. The aim of this study was to examine survival and causes of death in kidneyExpand
  • 340
  • 6
Implementation of a Protocol for ABO-Incompatible Kidney Transplantation – A Three-Center Experience With 60 Consecutive Transplantations
Background. A new protocol for ABO-incompatible kidney transplantation has recently been introduced. We report here on the joint experience of the implementation in Stockholm and Uppsala, Sweden andExpand
  • 181
  • 6
  • Open Access
Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab
Background. Historically, ABO-incompatible kidney transplantations have only been undertaken after splenectomy and unspecific plasmapheresis and with quadruple drug immunosuppression plus B-cellExpand
  • 243
  • 5
Pharmacodynamics of Rituximab in Kidney Allotransplantation
The anti‐CD20 antibody rituximab has recently gained interest as a B‐cell depleting agent in renal transplantation. However, little is known about the pharmacodynamics of rituximab in renalExpand
  • 133
  • 5
Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation.
BACKGROUND The purpose of pancreatic transplantation in insulin-dependent diabetic patients is to restore normoglycemia and thereby prevent the secondary complications of diabetes. However,Expand
  • 222
  • 4
Two Corticosteroid-Free Regimens—Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil—in Comparison with a Standard Triple Regimen in Renal Transplantation:
Background. The side effects associated with corticosteroids have led to efforts to minimize their use in renal transplant patients. In this study we compared two corticosteroid-free tacrolimus-basedExpand
  • 96
  • 4